# A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

> **NCT05625919** · PHASE1,PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

## Interventions

- **DRUG:** Sirolimus for Injection (Albumin Bound)

## Key facts

- **NCT ID:** NCT05625919
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-08
- **Primary completion:** 2024-11
- **Final completion:** 2024-11
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05625919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05625919, "A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05625919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*